L Tao, F Y Liang, X Lu, A K Yang, L Zhou, Q Zhang, X Zhang, C P Wu, H J Yang, L J Chu, C He, C Z Xu, J T Chen, P Han, Y Wang, X M Huang, M Song
{"title":"[经口机器人手术治疗扁桃体鳞状细胞癌：5个医疗中心157例分析]。","authors":"L Tao, F Y Liang, X Lu, A K Yang, L Zhou, Q Zhang, X Zhang, C P Wu, H J Yang, L J Chu, C He, C Z Xu, J T Chen, P Han, Y Wang, X M Huang, M Song","doi":"10.3760/cma.j.cn115330-20240806-00463","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> To explore the clinical application value of transoral robotic surgery (TORS) in the treatment of tonsil squamous cell carcinoma (TSCC). <b>Methods:</b> A retrospective analysis was conducted. The clinical data of 157 TSCC patients were collected who received TORS at five medical centers, namely, the Sun Yat-sen University Cancer Center, Sun Yat-sen Memorial Hospital, Eye Ear Nose and Throat Hospital of Fudan University, the First Affiliated Hospital of China Medical University, and Tongji Hospital of Tongji Medical College, from January 1 2017 to July 31 2022. There were 130 males and 27 females, aged 24-85 years. All patients were followed-up at least for 2 years (2-year group), among them, 99 patients had a follow-up of 3 years (3-year group). The overall survival (OS), progression-free survival (PFS), clinical stage, human papillomavirus (HPV) infection status were analyzed. SPSS 25.0 and SAS 9.4 were used for statistical analysis. <b>Results:</b> The OS and PFS of the 2-year group were 91.7% and 87.9%, respectively. The OS and PFS of the 3-year group were 85.9% and 82.8%, respectively. The prognosis of patients with locally early-stage was better than that of locally advanced patients, with the OS of 94.4% for T1-2 <i>vs</i>. 78.0% for T3 (<i>P</i>=0.005) and the PFS of 91.2% for T1-2 <i>vs</i>. 75.0% for T3 (<i>P</i>=0.011) in the 2-year group; the OS of 91.1% for T1-2 <i>vs</i>. 65.0% for T3 (<i>P</i>=0.004) and the PFS of 88.6% for T1-2 <i>vs</i>. 60.0% for T3 (<i>P</i>=0.002) in the 3-year group; and also, the OS of 90.0% for stage Ⅰ-Ⅱ <i>vs</i>. 79.5% for stage Ⅲ-Ⅳ (<i>P</i>=0.204) and the PFS of 86.7% for stage Ⅰ-Ⅱ <i>vs</i>. 76.9% for stage Ⅲ-Ⅳ (<i>P</i>=0.188) in the 3-year group. The prognosis of HPV-positive TSCC patients was better than that of HPV-negative patients in the 3-year group, with the OS of 90.9% for HPV-positive <i>vs</i>. 80.5% for HPV-negative (<i>P</i>=0.045) and the PFS of 90.9% for HPV-positive <i>vs</i>. 75.6% for HPV-negative (<i>P</i>=0.047). The average time of postoperative tracheal cannula indwelling was 25.1 days. The indwelling rate and average indwelling time of the postoperative nasogastric tube were 94.3% (148/157) and 8.5 days, respectively. <b>Conclusion:</b> TORS has outstanding survival benefits for TSCC patients. HPV-positive TSCC patients have a better prognosis than HPV-negative patients. TORS treatment of TSCC patients has advantages in postoperative recovery and quality of life.</p>","PeriodicalId":23987,"journal":{"name":"Chinese journal of otorhinolaryngology head and neck surgery","volume":"60 ","pages":"258-265"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Transoral robotic surgery of tonsillar squamous cell carcinoma: analysis of 157 cases from five medical centers].\",\"authors\":\"L Tao, F Y Liang, X Lu, A K Yang, L Zhou, Q Zhang, X Zhang, C P Wu, H J Yang, L J Chu, C He, C Z Xu, J T Chen, P Han, Y Wang, X M Huang, M Song\",\"doi\":\"10.3760/cma.j.cn115330-20240806-00463\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Objective:</b> To explore the clinical application value of transoral robotic surgery (TORS) in the treatment of tonsil squamous cell carcinoma (TSCC). <b>Methods:</b> A retrospective analysis was conducted. The clinical data of 157 TSCC patients were collected who received TORS at five medical centers, namely, the Sun Yat-sen University Cancer Center, Sun Yat-sen Memorial Hospital, Eye Ear Nose and Throat Hospital of Fudan University, the First Affiliated Hospital of China Medical University, and Tongji Hospital of Tongji Medical College, from January 1 2017 to July 31 2022. There were 130 males and 27 females, aged 24-85 years. All patients were followed-up at least for 2 years (2-year group), among them, 99 patients had a follow-up of 3 years (3-year group). The overall survival (OS), progression-free survival (PFS), clinical stage, human papillomavirus (HPV) infection status were analyzed. SPSS 25.0 and SAS 9.4 were used for statistical analysis. <b>Results:</b> The OS and PFS of the 2-year group were 91.7% and 87.9%, respectively. The OS and PFS of the 3-year group were 85.9% and 82.8%, respectively. The prognosis of patients with locally early-stage was better than that of locally advanced patients, with the OS of 94.4% for T1-2 <i>vs</i>. 78.0% for T3 (<i>P</i>=0.005) and the PFS of 91.2% for T1-2 <i>vs</i>. 75.0% for T3 (<i>P</i>=0.011) in the 2-year group; the OS of 91.1% for T1-2 <i>vs</i>. 65.0% for T3 (<i>P</i>=0.004) and the PFS of 88.6% for T1-2 <i>vs</i>. 60.0% for T3 (<i>P</i>=0.002) in the 3-year group; and also, the OS of 90.0% for stage Ⅰ-Ⅱ <i>vs</i>. 79.5% for stage Ⅲ-Ⅳ (<i>P</i>=0.204) and the PFS of 86.7% for stage Ⅰ-Ⅱ <i>vs</i>. 76.9% for stage Ⅲ-Ⅳ (<i>P</i>=0.188) in the 3-year group. The prognosis of HPV-positive TSCC patients was better than that of HPV-negative patients in the 3-year group, with the OS of 90.9% for HPV-positive <i>vs</i>. 80.5% for HPV-negative (<i>P</i>=0.045) and the PFS of 90.9% for HPV-positive <i>vs</i>. 75.6% for HPV-negative (<i>P</i>=0.047). The average time of postoperative tracheal cannula indwelling was 25.1 days. The indwelling rate and average indwelling time of the postoperative nasogastric tube were 94.3% (148/157) and 8.5 days, respectively. <b>Conclusion:</b> TORS has outstanding survival benefits for TSCC patients. HPV-positive TSCC patients have a better prognosis than HPV-negative patients. TORS treatment of TSCC patients has advantages in postoperative recovery and quality of life.</p>\",\"PeriodicalId\":23987,\"journal\":{\"name\":\"Chinese journal of otorhinolaryngology head and neck surgery\",\"volume\":\"60 \",\"pages\":\"258-265\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Chinese journal of otorhinolaryngology head and neck surgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/cma.j.cn115330-20240806-00463\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese journal of otorhinolaryngology head and neck surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn115330-20240806-00463","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
[Transoral robotic surgery of tonsillar squamous cell carcinoma: analysis of 157 cases from five medical centers].
Objective: To explore the clinical application value of transoral robotic surgery (TORS) in the treatment of tonsil squamous cell carcinoma (TSCC). Methods: A retrospective analysis was conducted. The clinical data of 157 TSCC patients were collected who received TORS at five medical centers, namely, the Sun Yat-sen University Cancer Center, Sun Yat-sen Memorial Hospital, Eye Ear Nose and Throat Hospital of Fudan University, the First Affiliated Hospital of China Medical University, and Tongji Hospital of Tongji Medical College, from January 1 2017 to July 31 2022. There were 130 males and 27 females, aged 24-85 years. All patients were followed-up at least for 2 years (2-year group), among them, 99 patients had a follow-up of 3 years (3-year group). The overall survival (OS), progression-free survival (PFS), clinical stage, human papillomavirus (HPV) infection status were analyzed. SPSS 25.0 and SAS 9.4 were used for statistical analysis. Results: The OS and PFS of the 2-year group were 91.7% and 87.9%, respectively. The OS and PFS of the 3-year group were 85.9% and 82.8%, respectively. The prognosis of patients with locally early-stage was better than that of locally advanced patients, with the OS of 94.4% for T1-2 vs. 78.0% for T3 (P=0.005) and the PFS of 91.2% for T1-2 vs. 75.0% for T3 (P=0.011) in the 2-year group; the OS of 91.1% for T1-2 vs. 65.0% for T3 (P=0.004) and the PFS of 88.6% for T1-2 vs. 60.0% for T3 (P=0.002) in the 3-year group; and also, the OS of 90.0% for stage Ⅰ-Ⅱ vs. 79.5% for stage Ⅲ-Ⅳ (P=0.204) and the PFS of 86.7% for stage Ⅰ-Ⅱ vs. 76.9% for stage Ⅲ-Ⅳ (P=0.188) in the 3-year group. The prognosis of HPV-positive TSCC patients was better than that of HPV-negative patients in the 3-year group, with the OS of 90.9% for HPV-positive vs. 80.5% for HPV-negative (P=0.045) and the PFS of 90.9% for HPV-positive vs. 75.6% for HPV-negative (P=0.047). The average time of postoperative tracheal cannula indwelling was 25.1 days. The indwelling rate and average indwelling time of the postoperative nasogastric tube were 94.3% (148/157) and 8.5 days, respectively. Conclusion: TORS has outstanding survival benefits for TSCC patients. HPV-positive TSCC patients have a better prognosis than HPV-negative patients. TORS treatment of TSCC patients has advantages in postoperative recovery and quality of life.
期刊介绍：
Chinese journal of otorhinolaryngology head and neck surgery is a high-level medical science and technology journal sponsored and published directly by the Chinese Medical Association, reflecting the significant research progress in the field of otorhinolaryngology head and neck surgery in China, and striving to promote the domestic and international academic exchanges for the purpose of running the journal.
Over the years, the journal has been ranked first in the total citation frequency list of national scientific and technical journals published by the Documentation and Intelligence Center of the Chinese Academy of Sciences and the China Science Citation Database, and has always ranked first among the scientific and technical journals in the related fields.
Chinese journal of otorhinolaryngology head and neck surgery has been included in the authoritative databases PubMed, Chinese core journals, CSCD.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
